These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 28368426)

  • 1. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
    Ohm AM; Tan AC; Heasley LE; Reyland ME
    Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PKCδ regulates integrin αVβ3 expression and transformed growth of K-ras dependent lung cancer cells.
    Symonds JM; Ohm AM; Tan AC; Reyland ME
    Oncotarget; 2016 Apr; 7(14):17905-19. PubMed ID: 26918447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.
    Symonds JM; Ohm AM; Carter CJ; Heasley LE; Boyle TA; Franklin WA; Reyland ME
    Cancer Res; 2011 Mar; 71(6):2087-97. PubMed ID: 21335545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
    Jin H; Jang Y; Cheng N; Li Q; Cui PF; Zhou ZW; Jiang HL; Cho MH; Westover KD; Tan QY; Xu CX
    J Exp Clin Cancer Res; 2019 Apr; 38(1):165. PubMed ID: 30987652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
    Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
    Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein kinase C delta is required for survival of cells expressing activated p21RAS.
    Xia S; Forman LW; Faller DV
    J Biol Chem; 2007 May; 282(18):13199-210. PubMed ID: 17350960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of RAS family members confers resistance to ROS1 targeting drugs.
    Cargnelutti M; Corso S; Pergolizzi M; Mévellec L; Aisner DL; Dziadziuszko R; Varella-Garcia M; Comoglio PM; Doebele RC; Vialard J; Giordano S
    Oncotarget; 2015 Mar; 6(7):5182-94. PubMed ID: 25691052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents.
    Ischenko I; Zhi J; Hayman MJ; Petrenko O
    Oncotarget; 2017 Mar; 8(11):17995-18009. PubMed ID: 28152508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
    Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
    Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.
    Yu JA; Li H; Meng X; Fullerton DA; Nemenoff RA; Mitchell JD; Weyant MJ
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1479-85. PubMed ID: 23026567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyisoprenylated Cysteinyl Amide Inhibitors Deplete K-Ras and Induce Caspase-dependent Apoptosis in Lung Cancer Cells.
    Nkembo AT; Amissah F; Ntantie E; Poku RA; Salako OO; Ikpatt OF; Lamango NS
    Curr Cancer Drug Targets; 2019; 19(10):838-851. PubMed ID: 30914025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach.
    Caiola E; Falcetta F; Giordano S; Marabese M; Garassino MC; Broggini M; Pastorelli R; Brunelli L
    J Exp Clin Cancer Res; 2018 Dec; 37(1):302. PubMed ID: 30514331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WT1 enhances proliferation and impedes apoptosis in KRAS mutant NSCLC via targeting cMyc.
    Wu C; Wang S; Xu C; Tyler A; Li X; Andersson C; Oji Y; Sugiyama H; Chen Y; Li A
    Cell Physiol Biochem; 2015; 35(2):647-62. PubMed ID: 25613309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
    Ihle NT; Byers LA; Kim ES; Saintigny P; Lee JJ; Blumenschein GR; Tsao A; Liu S; Larsen JE; Wang J; Diao L; Coombes KR; Chen L; Zhang S; Abdelmelek MF; Tang X; Papadimitrakopoulou V; Minna JD; Lippman SM; Hong WK; Herbst RS; Wistuba II; Heymach JV; Powis G
    J Natl Cancer Inst; 2012 Feb; 104(3):228-39. PubMed ID: 22247021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
    Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
    Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in
    Mehta AK; Hua K; Whipple W; Nguyen MT; Liu CT; Haybaeck J; Weidhaas J; Settleman J; Singh A
    Sci Signal; 2017 Sep; 10(496):. PubMed ID: 28900044
    [No Abstract]   [Full Text] [Related]  

  • 20. PKCdelta survival signaling in cells containing an activated p21Ras protein requires PDK1.
    Xia S; Chen Z; Forman LW; Faller DV
    Cell Signal; 2009 Apr; 21(4):502-8. PubMed ID: 19146951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.